---
title: "ACCO: Q2 2026 results surpassed expectations, led by EPOS acquisition and robust Americas growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294412365.md"
description: "Q2 2026 sales and adjusted EPS exceeded outlook, driven by the EPOS acquisition and strong Americas performance, despite global declines in Workspace Solutions and Technology Peripherals. Full-year guidance was raised, with continued focus on cost reductions and integration ofriginal document: Acco Brands Corporation [ACCO] Slides Release — Jul. 31 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T20:32:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294412365.md)
  - [en](https://longbridge.com/en/news/294412365.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294412365.md)
generator: "portal-rs"
---

# ACCO: Q2 2026 results surpassed expectations, led by EPOS acquisition and robust Americas growth

Q2 2026 sales and adjusted EPS exceeded outlook, driven by the EPOS acquisition and strong Americas performance, despite global declines in Workspace Solutions and Technology Peripherals. Full-year guidance was raised, with continued focus on cost reductions and integration of EPOS.

Original document: Acco Brands Corporation \[ACCO\] Slides Release — Jul. 31 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ACCO.US](https://longbridge.com/en/quote/ACCO.US.md)

## Related News & Research

- [ACCO Brands Q2 sales beat on EPOS acquisition boost, outlook raised](https://longbridge.com/en/news/294410505.md)
- [ACCO Brands to Acquire Trust | ACCO Stock News](https://longbridge.com/en/news/295923217.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**